


REMARKS

Claims 1-2, 4-6 and 8 have been canceled by this amendment. Currently claims 3, 7, and 9-14 are pending in the application. The subject matter of Claims 1-2, 4-6 and 8 have been cancelled and rewritten as new Claims 9-14 in a format more acceptable to the Patent Office. Hence, there is no new matter. Applicants have attached an abstract on a separate sheet of paper as required by US practice. Applicants have amended the specification for purposes of adding the priority information.

Respectfully submitted,



Bonnie L. Deppenbrock
Attorney for Applicants
Registration No.28,209

Date: 12/18/01
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Phone: 919-483-1577
Facsimile: 919-483-7988